252 related articles for article (PubMed ID: 31750596)
1. Rates of clinically significant prostate cancer in African Americans increased significantly following the 2012 US Preventative Services Task Force recommendation against prostate specific antigen screening: A Single Institution Retrospective Study.
Arace J; Flores V; Monaghan T; Robins D; Karanikolas N; Winer A; Weiss J
Int J Clin Pract; 2020 Feb; 74(2):e13447. PubMed ID: 31750596
[TBL] [Abstract][Full Text] [Related]
2. Abrogation of survival disparity between Black and White individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
Kim IE; Jang TL; Kim S; Modi PK; Singer EA; Elsamra SE; Kim IY
Cancer; 2020 Dec; 126(23):5114-5123. PubMed ID: 32888321
[TBL] [Abstract][Full Text] [Related]
3. African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in serum prostate specific antigen.
Fuletra JG; Kamenko A; Ramsey F; Eun DD; Reese AC
Can J Urol; 2018 Feb; 25(1):9193-9198. PubMed ID: 29524974
[TBL] [Abstract][Full Text] [Related]
4. The impact of African American race on prostate cancer detection on repeat prostate biopsy in a veteran population.
Sterling WA; Weiner J; Schreiber D; Mehta K; Weiss JP
Int Urol Nephrol; 2016 Dec; 48(12):2015-2021. PubMed ID: 27580731
[TBL] [Abstract][Full Text] [Related]
5. Do African-American men need separate prostate cancer screening guidelines?
Shenoy D; Packianathan S; Chen AM; Vijayakumar S
BMC Urol; 2016 May; 16(1):19. PubMed ID: 27165293
[TBL] [Abstract][Full Text] [Related]
6. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
[TBL] [Abstract][Full Text] [Related]
7. Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates.
Bhindi B; Mamdani M; Kulkarni GS; Finelli A; Hamilton RJ; Trachtenberg J; Zlotta AR; Evans A; van der Kwast TH; Toi A; Fleshner NE
J Urol; 2015 May; 193(5):1519-24. PubMed ID: 25481037
[TBL] [Abstract][Full Text] [Related]
8. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy.
Jeong IG; Dajani D; Verghese M; Hwang J; Cho YM; Hong JH; Kim CS; Ahn H; Ro JY
Urol Oncol; 2016 Jan; 34(1):3.e9-14. PubMed ID: 26345648
[TBL] [Abstract][Full Text] [Related]
9. Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?
Hudson MA; Luo S; Chrusciel T; Yan Y; Grubb RL; Carson K; Scherrer JF
Urol Oncol; 2014 Jan; 32(1):34.e9-18. PubMed ID: 23506962
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer screening and detection in inner-city and underserved men.
Anai S; Pendleton J; Wludyka P; Williams C; Nelms L; Pettaway C; Rosser CJ
J Natl Med Assoc; 2006 Apr; 98(4):515-9. PubMed ID: 16623063
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
12. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
13. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
[TBL] [Abstract][Full Text] [Related]
14. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
15. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
[TBL] [Abstract][Full Text] [Related]
16. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
Eapen RS; Herlemann A; Washington SL; Cooperberg MR
Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
[TBL] [Abstract][Full Text] [Related]
17. Changes observed in prostate biopsy practices in an inner city hospital with a high risk patient population following the 2012 uspstf psa screening recommendations.
Tam AW; Khusid J; Inoyatov I; Becerra AZ; Davila J; Chouhan JD; Weiss JP; Hyacinthe LM; McNeil BK; Winer AG
Int Braz J Urol; 2018; 44(4):697-703. PubMed ID: 29617073
[TBL] [Abstract][Full Text] [Related]
18. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
[TBL] [Abstract][Full Text] [Related]
19. Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening.
Banerji JS; Wolff EM; Massman JD; Odem-Davis K; Porter CR; Corman JM
J Urol; 2016 Jan; 195(1):66-73. PubMed ID: 26254722
[TBL] [Abstract][Full Text] [Related]
20. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
Schenk JM; Newcomb LF; Zheng Y; Faino AV; Zhu K; Nyame YA; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW
J Urol; 2020 Apr; 203(4):727-733. PubMed ID: 31651227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]